Introduction: A simultaneous integrated boost (SIB) leads to less acute toxicity. Less is known for late toxicity due to SIB. In this first and only randomized trial, two-years toxicity is analysed.
Materials and methods: Physician-assessed toxicity, using the LENT SOMA scale, and photographs, analysed with the BCCT.core software, was examined for 150 patients, randomized between SIB and sequential boost (SEB).
Results: Differences in physician-assessed two-years toxicity and photographic analysis between SIB and SEB are very small and not significant.
Conclusion: There is no indication that a SIB leads to an excess in toxicity or worse cosmetic outcome at 2 years.
Keywords: Breast cancer boost; Sequental boost; Simultaneous ingetrated boost.
Copyright © 2021 Elsevier B.V. All rights reserved.